Iceland· IS-IS/1/18/030/01
Cefazolina Normon
A cefazolin product containing lidocainum inn hýdróklóríð,cefazolinum inn natríum, registered in Iceland by Laboratorios Normon, S.A.. The same ATC class is registered in 18 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Cefazolin is registered in 18 of 19 countries.
Countries holding a registration under ATC J01DB04 (cefazolin), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 11 of them publish a price we can compare per daily dose
Cefazolin · ATC J01DB04
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of cefazolin costs, country by country.
Normalised to the WHO defined daily dose (3 g), the median price runs from $8.27 in Spain to $16.85 in Switzerland — a ×2.0 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Cefazolin · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$16.85
- ES Spain$8.27
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Lidocainum INN hýdróklóríð,Cefazolinum INN natríum
- Manufacturer
- Laboratorios Normon, S.A.
- Country
- Iceland (IS)
- ATC code
- J01DB04
- ATC class
- Cefazolin
- Defined daily dose
- 3 g, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 8, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
166 interactions on record for cefazolin.
Graded by severity as the source publishes them — 20 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cefazolin · interactions on record
166 records
- 20 moderate
- 2 minor
- 144 info
Most severe, free to view
- Sodium picosulfateA06AB08moderate
- NeomycinA07AA01moderate
- StreptomycinA07AA04moderate
- KanamycinA07AA08moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01DB04
Cefazolin, as other registers publish it.
- CzechiaAZEPOMedochemie Bohemia, spol. s r.o., Praha
- CzechiaAZEPOMedochemie Bohemia, spol. s r.o., Praha
- CzechiaAZEPOMedochemie Bohemia, spol. s r.o., Praha
- CzechiaAZEPOMedochemie Bohemia, spol. s r.o., Praha
- CzechiaAZEPOMedochemie Bohemia, spol. s r.o., Praha
- PolandBiofazolinZakłady Farmaceutyczne POLPHARMA S.A.
- ItalyCEFAZILITALFARMACO S.P.A.
- United StatesCefazolinSandoz Inc
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Spain · Cefazolina Sala
- Italy · Cefazolina Teva
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bc86863f-0fe6-4bad-8d25-a4e92012beb0 GET /v1/drugs/bc86863f-0fe6-4bad-8d25-a4e92012beb0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyfsstofn og leysir, lausn",
"source": "lyfjastofnun",
"atc_raw": "J01DB04",
"marketed": false,
"strength": "í vöðva 1 g",
"ma_number": "IS/1/18/030/01",
"substance": "Lidocainum INN hýdróklóríð,Cefazolinum INN natríum",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "43168"
}See everything about cefazolin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.